Christopher Paul Cannon
Brigham and Women's Hospital
4 papers in the Anchorcite directory, published between 2004 and 2019, cited 23,161 times in total.
ORCID profileResearch topics
- Acute Myocardial Infarction Research · 3 papers
- Lipoproteins and Cardiovascular Health · 2 papers
- Antiplatelet Therapy and Cardiovascular Diseases · 1 paper
- Coronary Interventions and Diagnostics · 1 paper
- Diabetes Treatment and Management · 1 paper
- Acute Kidney Injury Research · 1 paper
Frequent co-authors
- Kenneth W. Mahaffey · 2 papers
- Allan M. Skene · 2 papers
- Eugene Braunwald · 2 papers
- Lars C. Wallentin · 1 paper
- Richard Clinton Becker · 1 paper
- Andrzej Budaj · 1 paper
- Håkan Emanuelsson · 1 paper
- Claes Held · 1 paper
Papers
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine · 2009 · 7,173 citations
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose,…
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2019 · 6,422 citations
BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal…
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine · 2004 · 4,966 citations
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10…
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine · 2015 · 4,600 citations
BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.…
Metadata from OpenAlex (CC0).